The heart of insitro’s strategy is the combination of novel, cutting edge methods in machine learning, high-throughput biology and disease modeling that address key bottlenecks in the drug development pipeline. To accomplish that, we are putting together an incredible team of highly talented leaders in translational science who want to make a difference to this important problem. In this role, you will play a key part in building our Translational Genetics effort as a member of insitro’s Translational Science department. As the Translational Genetics lead, you will be responsible for the integration of human genetics data with multidimensional phenotypic and OMICS data to identify and validate drug targets in our core therapeutic areas on cross-functional teams.
You will oversee and guide the use of cutting edge statistical approaches and workflows to analyze large-scale human cohorts with genetic and multi-dimensional, multi-modality phenotypic data. These data sets will be obtained from public sources, as well as private datasets generated in-house and obtained through our collaborations. You will use genetic association and other statistical genetics techniques that involve integration of genetic, genomic and clinical data to (i) guide in vitro disease model development, (ii) select candidate drug targets; and (ii) support drug development programs.
Your primary duties will be to:
You will be joining as the founding team of a biotech startup that has long-term stability due to significant funding, but yet is very much in formation. A lot can change in this early and exciting phase, providing many opportunities for significant impact. You will work closely with a very talented team, learn a broad range of skills, and help shape insitro’s culture, strategic direction, and outcomes. Join us, and help make a difference to patients!
Benefits at insitro
insitro is a drug discovery and development company using machine learning and data generation at scale to transform the way that drugs are discovered and delivered to patients. We rely on human genetic cohorts, human-derived cellular disease models, and high-throughput biology and chemistry to identify coherent patient segments, actionable therapeutic targets, and new or existing chemical matter. The goal is to deliver predictive insights to improve the probability of success and reduce the number of costly dead ends along the R&D journey. The company has established enabling collaborations with Gilead in NASH and Bristol Myers Squibb in ALS and is building a pipeline of wholly owned and partnered medicines leveraging its unique insights on patient biomarkers, targets, and molecules. insitro is located in South San Francisco, CA and has raised over $600M from top tech, biotech, and crossover investors since formation in 2018. For more information on insitro, please visit the company’s website at www.insitro.com.
Your application was submitted successfully.